European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Posted:
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) injection.
As general-purpose AI like ChatGPT and Gemini make its way into people's everyday lives today, domain-specific ones like AI in cancer are also advancing, with only funding and critical infrastructure standing in the way of clinical use, according to one…
Infrastructure is easy to overlook and underinvest in. Roads, bridges, and electrical grids fade into the background, until a failure makes them impossible to ignore.
The same is becoming true for AI in healthcare. Over the past several years, health…
Attendees
Sponsors and Exhibitors
Contact us